Praxis’ Seizure Drug Demonstrates ‘Impressive’ Efficacy in Mid-Stage Trial
Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that of its closest competitors.Read more:
biospace.comBiotechnology